DBV Technologies
Develops epicutaneous immunotherapy (EPIT) patch technology for food allergies.
DBV | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417345 (+3 more)
- LEI:
- 969500PVBQFWQKVDMD80
- Country:
- France
- Address:
- 107 AVENUE DE LA REPUBLIQUE, 92320 CHATILLON
- Sector:
- Manufacturing
Description
DBV Technologies is a clinical-stage biopharmaceutical company developing treatments for food allergies and other immunological diseases. The company's core technology is Viaskin®, a proprietary investigational platform based on epicutaneous immunotherapy (EPIT). This non-invasive patch technology is designed to re-educate the immune system by delivering minimal amounts of antigens through intact skin. DBV's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergies in pediatric patients. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, with the platform holding potential for applications beyond food allergies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2014-10-22 08:31 |
DBV S.A annonce le prix d'une offre globale d'actions nouvelles
|
French | 113.1 KB | ||
| 2014-10-22 08:31 |
DBV Technologies S.A. Announces Pricing of Global Offering
|
English | 110.7 KB | ||
| 2014-10-20 20:01 |
DBV Technologies S.A. annonce une offre globale d'actions nouvelles
|
French | 121.8 KB | ||
| 2014-10-20 20:01 |
DBV Technologies S.A. Announces Proposed Global Offering
|
English | 144.9 KB | ||
| 2014-10-16 08:31 |
DBV annonce le dépôt d'un « amendment » au F-1
|
French | 111.1 KB | ||
| 2014-10-14 19:00 |
DBV Announces Topline Financial Results for First Nine Months
|
English | 82.8 KB | ||
| 2014-10-14 19:00 |
Produits opérationnels et situation nette de trésorerie Q3 2014
|
French | 75.6 KB | ||
| 2014-09-22 19:30 |
DBV annonce que le critère primaire d'efficacité de VIPES est atteint
|
French | 136.1 KB | ||
| 2014-09-22 19:30 |
DBV Announces Primary Endpoint Met in VIPES study
|
English | 148.8 KB | ||
| 2014-08-26 09:01 |
DBV to Attend the Goldman Sachs European Biotech Symposium
|
English | 68.9 KB | ||
| 2014-08-26 09:01 |
DBV invitée au European Biotech Symposium de Goldman Sachs
|
French | 97.7 KB | ||
| 2014-08-12 11:09 |
Monthly information regarding the total number of voting rights
|
English | 80.4 KB | ||
| 2014-08-12 11:09 |
Information relative au droit de vote
|
French | 124.9 KB | ||
| 2014-08-01 11:59 |
Monthly information regarding the total number of voting rights
|
English | 17.9 KB | ||
| 2014-08-01 11:59 |
Information relative au droit de vote
|
French | 17.8 KB |
Automate Your Workflow. Get a real-time feed of all DBV Technologies filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for DBV Technologies
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DBV Technologies via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-09 | N/A | Other | Other | 2,483,161 | 7,449,483.00 EUR |
Peer Companies
